Skip to NavigationSkip to content's weekly COVID-19 news round-up

Published on 22/04/20 at 12:07pm
Photo by CDC

Hydroxychloroquine has faced setbacks as a potential COVID-19 treatment, as it failed a clinical trial in France and a study in China found it did not speed up recovery from the coronavirus.

In other news, new research suggests that social distancing could be put in place until 2022 while the FDA is warning that the pandemic will slow down the review of drugs for approval.

1. Hydroxychloroquine fails COVID-19 clinical trial in FrancePublished on 20/04/2020

The malaria treatment hydroxychloroquine is facing further scrutiny as a coronavirus treatment after failed trials in France.

2. Intermittent social distancing could last until 2022, according to a new studyPublished on 16/04/2020

Social distancing that has been put in place to stem the spread of COVID-19 coronavirus could be implemented up until 2022, according to new research.

3. New Chinese study shows hydroxychloroquine does not speed up COVID-19 recoveryPublished 15/04/2020

The anti-malaria drug hydroxychloroquine does not speed up recovery from COVID-19, according to a new Chinese study.

4. FDA cautions that drug reviews will be slower due to COVID-19Published 17/04/2020

The FDA has warned that they may not be able to sustain its current levels of timely reviews and approvals of marketing applications due to staff being reallocated to working on the COVID-19 coronavirus pandemic.

5. Sanofi and GSK set aside rivalry with "unprecedented" COVID-19 vaccine partnership – Published on 15/04/2020

Usual rivals Sanofi and GlaxoSmithKline have said they are to put aside competition with the forging of a new “unprecedented collaboration” in the pursuit of an adjuvanted vaccine against the COVID-19 pandemic.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches